Assessing deviations for HPCs obtained during COVID-19 (ADHOC): Evaluating impact of the COVID-19 pandemic on cellular therapy products and processes, the BEST collaborative study.
COVID-19
cellular therapy product quality
cryopreservation
hematopoietic stem cell
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
21
12
2022
received:
20
11
2022
accepted:
26
12
2022
medline:
12
4
2023
pubmed:
17
3
2023
entrez:
16
3
2023
Statut:
ppublish
Résumé
The success of allogeneic hematopoietic stem cell transplantation is dependent on a world-wide network of collection centers providing donations that predominantly have been infused as fresh cells. The logistics chain that supports the just-in-time delivery model for stem cell and immunotherapy products was severely stressed by the COVID pandemic, and in early 2020 a number of national and international bodies recommended that cells should be cryopreserved at the collection or transplant center to avoid interruptions in their acquisition or delivery to patients who had started conditioning. To assess the potential consequences of such pandemic-related deviations to normal practice, we surveyed nine international laboratories to determine if the characteristics or transplant outcomes of allogeneic stem cell donations differed in the immediate periods before and after the switch to routine cryopreservation. Nine centers on two continents provided data for 72 HSC donations just before, and 71 just after, switching to cryopreservation for allogeneic HSC products. No statistically significant differences between the period before and after cryopreservation were noted for time from product collection to receipt, product temperature at receipt, or CD34 While there were no apparent changes to most parameters studied, there was an indication of slower neutrophil engraftment that will need to be examined in larger, longer term studies.
Sections du résumé
BACKGROUND
The success of allogeneic hematopoietic stem cell transplantation is dependent on a world-wide network of collection centers providing donations that predominantly have been infused as fresh cells. The logistics chain that supports the just-in-time delivery model for stem cell and immunotherapy products was severely stressed by the COVID pandemic, and in early 2020 a number of national and international bodies recommended that cells should be cryopreserved at the collection or transplant center to avoid interruptions in their acquisition or delivery to patients who had started conditioning.
STUDY DESIGN
To assess the potential consequences of such pandemic-related deviations to normal practice, we surveyed nine international laboratories to determine if the characteristics or transplant outcomes of allogeneic stem cell donations differed in the immediate periods before and after the switch to routine cryopreservation.
RESULTS
Nine centers on two continents provided data for 72 HSC donations just before, and 71 just after, switching to cryopreservation for allogeneic HSC products. No statistically significant differences between the period before and after cryopreservation were noted for time from product collection to receipt, product temperature at receipt, or CD34
DISCUSSION
While there were no apparent changes to most parameters studied, there was an indication of slower neutrophil engraftment that will need to be examined in larger, longer term studies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
782-790Informations de copyright
© 2023 AABB.
Références
Worel N, Shaw BE, Aljurf M, Koh M, Seber A, Weisdorf D, et al. Changes in hematopoietic cell transplantation practices in response to COVID-19: a survey from the worldwide network for blood & marrow transplantation. Transplant Cell Ther. 2021;27(3):270e1-6.
Lazarus HM, Kan F, Tarima S, Champlin RE, Confer DL, Frey N, et al. Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant. Biol Blood Marrow Transplant. 2009;15(5):589-96.
Frey NV, Lazarus HM, Goldstein SC. Has allogeneic stem cell cryopreservation been given the ‘cold shoulder’? An analysis of the pros and cons of using frozen versus fresh stem cell products in allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38(6):399-405.
Hsu JW, Farhadfar N, Murthy H, Logan BR, Bo-Subait S, Frey N, et al. The effect of donor graft cryopreservation on allogeneic hematopoietic cell transplantation outcomes: a Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 pandemic. Transplant Cell Ther. 2021;27(6):507-16.
Thibodeaux SR, McKenna DH, Szczepiorkowski ZM, Fontaine MJ, Kelley L, Reems JA, et al. A multicenter evaluation of heterogeneity in cellular therapy processing laboratory procedure times to assess workload capacity. Transfusion. 2020;60(8):1811-20.
Novitzky-Basso I, Remberger M, Chen C, Pasic I, Lam W, Law A, et al. Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. Eur J Haematol. 2022;108(1):61-72.
Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, et al. Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia. Biol Blood Marrow Transplant. 2020;26(7):e161-e6.
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, et al. Real-world issues and potential solutions in hematopoietic cell transplantation during the COVID-19 pandemic: perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020;26(12):2181-9.
Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, et al. Graft cryopreservation does not impact overall survival after allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2020;26(7):1312-7.
Jacob RP, Flynn J, Devlin SM, Maloy M, Giralt SA, Maslak P, et al. Universal engraftment after allogeneic hematopoietic cell transplantation using cryopreserved CD34-selected grafts. Transplant Cell Ther. 2021;27(8):697e1-5.
Devine S, Kuxhausen M, Spellman SR, Fretham C, Woo Ahn K, Stefanski HE, et al. Cryopreservation of allogeneic hematopoietic cell grafts did not adversely affect early post-transplant survival during the first six months of the COVID-19 pandemic. Blood. 2021;138(Supplement 1):2846.
Maurer K, Kim HT, Kuczmarski TM, Garrity HM, Weber A, Reynolds CG, et al. Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Adv. 2021;5(23):5140-9.
Bankova AK, Caveney J, Yao B, Ramos TL, Bogeholz J, Heydari K, et al. Real-world experience of cryopreserved allogeneic hematopoietic grafts during the COVID-19 pandemic: a single-center report. Transplant Cell Ther. 2022;28(4):215e1-e10.
Fernandez-Sojo J, Azqueta C, Valdivia E, Martorell L, Medina-Boronat L, Martinez-Llonch N, et al. Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic? Bone Marrow Transplant. 2021;56(10):2489-96.
Fadeyi E, Mamo YT, Saha AK, Wilson E, Pomper G. The viability of hematopoietic progenitor cell grafts after cryopreservation does not predict delayed engraftment in allogeneic hematopoietic stem cell transplantation. Lab Med. 2022;53(5):509-13.
Wiercinska E, Schlipfenbacher V, Bug G, Bader P, Verbeek M, Seifried E, et al. Allogeneic transplant procurement in the times of COVID-19: quality report from the central European cryopreservation site. J Transl Med. 2021;19(1):145.
Mfarrej B, Lemarie C, Granata A, Pagliardini T, Malenfant C, Lignee P, et al. Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic. Bone Marrow Transplant. 2021;56(8):2013-5.
Purtill D, Antonenas V, Chiappini P, Tong D, O'Flaherty E, Bajel A, et al. Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic. Blood Adv. 2020;4(17):4147-50.
Valentini CG, Chiusolo P, Bianchi M, Metafuni E, Orlando N, Giammarco S, et al. Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal. Cytotherapy. 2021;23(7):635-40.
Joris MM, Schmidt AH, Bernas SN, Feinberg J, Sacchi N, Elmoazzen H, et al. Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-report from World Marrow Donor Association. Bone Marrow Transplant. 2022;57(6):1021-4.
Pidala J, Mupfudze TG, Payton T, Barker J, Perales MA, Shaw BE, et al. Urgent time to allogeneic hematopoietic cell transplantation: a national survey of transplant physicians and unrelated donor search coordinators facilitated by the histocompatibility advisory group to the National Marrow Donor Program. Biol Blood Marrow Transplant. 2019;25(12):2501-6.
Passweg JR, Baldomero H, Chabannon C, Corbacioglu S, de la Camara R, Dolstra H, et al. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplant. 2022;57(5):742-52.
Schmidt AH, Buk D, Bernas SN, Mengling T, Neujahr E, van den Brink MRM. A DKMS (German Bone Marrow Donor Center) view on cryopreservation of unrelated donor stem cell products during the Covid-19 pandemic. Am J Hematol. 2021;96(3):E91-E2.